Literature DB >> 15868587

Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5.

Peter F Ehrlich1, Michael L Ritchey, Tomas E Hamilton, Gerald M Haase, San Ou, Norman Breslow, Paul Grundy, Daniel Green, Patricia Norkool, Jennifer Becker, Robert C Shamberger.   

Abstract

BACKGROUND/
PURPOSE: Surgical technique impacts both local tumor stage and risk of local recurrence in Wilms' tumor. A surgical quality assurance program was part of National Wilms' Tumor Study-5 to assess protocol compliance.
METHODS: Surgical checklists, operative, and pathology reports were reviewed concurrently to arrive at the final local tumor stage. If a protocol violation occurred, a letter was sent to the responsible surgeon. Tumor laterality, extent, type of resection, contralateral exploration, node involvement, spills, and local recurrence were reviewed. Relative risk and logistic regression analyses were performed.
RESULTS: There were 1305 nephrectomies. Lymph node sampling was not performed in 117 (9%) patients: stage I, 41 (11.5%), stage II, 57 (12%), and stage III, 19 (4%). Of importance, 41% (187/457) of stage III cases were designated stage III solely on the basis of positive lymph nodes. Tumor spill occurred in 19.3% (253/1305) of children. Fifty-four local spills were in stage II tumors and 97 in stage III. Diffuse spill occurred in 102 patients with stage III tumors. Seventeen preoperative and 13 intraoperative biopsies were performed. Intraoperative tumor rupture was the most common cause of tumor spill accounting for 139 (55%) spills. Nineteen (7.5%) children were upstaged, receiving more intensive therapy because of spill. Included in the group were 3 of 17 preoperative biopsies and 5 of 13 intraoperative biopsies. Spills (13/253) were determined to be avoidable. Eight were biopsies, 5 because tumor was transected in the renal vein (4) or ureter (1). In stage II patients where lymph nodes were not sampled, there is an increase in local relapse rate that did not achieve statistical significance because of the small number of events.
CONCLUSIONS: Although most surgeons complied with the surgical guidelines, numerous deviations were identified including failure to sample lymph nodes (117 cases) and unnecessary biopsies leading to tumor spill (30 cases). Protocol violations have an adverse impact on tumor staging, potentially increasing the risk for local tumor recurrence or intensity and toxicity of therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15868587     DOI: 10.1016/j.jpedsurg.2004.09.044

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  23 in total

Review 1.  Neonatal tumours.

Authors:  Kokila Lakhoo; Helen Sowerbutts
Journal:  Pediatr Surg Int       Date:  2010-10-19       Impact factor: 1.827

2.  Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.

Authors:  James I Geller; Peter F Ehrlich; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Eric J Gratias; Arlene Naranjo; Jeffrey S Dome; Elizabeth J Perlman
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

3.  Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.

Authors:  Najat C Daw; Yueh-Yun Chi; John A Kalapurakal; Yeonil Kim; Fredric A Hoffer; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Elizabeth A Mullen; Anne B Warwick; Paul E Grundy; Arnold C Paulino; Eric Gratias; Deborah Ward; James R Anderson; Geetika Khanna; Brett Tornwall; Conrad V Fernandez; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2020-03-05       Impact factor: 44.544

4.  Impact of central surgical review in a study of malignant germ cell tumors.

Authors:  Deborah F Billmire; Frederick J Rescorla; Jonathan H Ross; Marc G Schlatter; Bryan J Dicken; Mark D Krailo; Carlos Rodriguez-Galindo; Thomas A Olson; John W Cullen; A Lindsay Frazier
Journal:  J Pediatr Surg       Date:  2014-12-17       Impact factor: 2.545

Review 5.  Wilms' tumor- roadmaps of management.

Authors:  Yogesh Kumar Sarin; Sushmita Nitin Bhatnagar
Journal:  Indian J Pediatr       Date:  2012-05-04       Impact factor: 1.967

6.  Volume-outcome effects for children undergoing resection of renal malignancies.

Authors:  Jason R Axt; Andrew J Murphy; Patrick G Arbogast; Harold N Lovvorn
Journal:  J Surg Res       Date:  2012-04-24       Impact factor: 2.192

7.  Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.

Authors:  Peter F Ehrlich; James R Anderson; Michael L Ritchey; Jeffrey S Dome; Daniel M Green; Paul E Grundy; Elizabeth J Perlman; John A Kalapurakal; Norman E Breslow; Robert C Shamberger
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

8.  Inter-rater reliability of surgical reviews for AREN03B2: a COG renal tumor committee study.

Authors:  Thomas E Hamilton; Douglas Barnhart; Kenneth Gow; Fernando Ferrer; Jessica Kandel; Richard Glick; Roshni Dasgupta; Arlene Naranjo; Ying He; Eric Gratias; James Geller; Elizabeth Mullen; Peter Ehrlich
Journal:  J Pediatr Surg       Date:  2013-10-05       Impact factor: 2.545

9.  Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee.

Authors:  Kenneth W Gow; Douglas C Barnhart; Thomas E Hamilton; Jessica J Kandel; Mike K S Chen; Fernando A Ferrer; Mitchell R Price; Elizabeth A Mullen; James I Geller; Eric J Gratias; Nancy Rosen; Geetika Khanna; Arlene Naranjo; Michael L Ritchey; Paul E Grundy; Jeffrey S Dome; Peter F Ehrlich
Journal:  J Pediatr Surg       Date:  2013-01       Impact factor: 2.545

10.  Use of nephron sparing surgery and impact on survival in children with Wilms tumor: a SEER analysis.

Authors:  Hsin-Hsiao S Wang; Michael R Abern; Nicholas G Cost; David I Chu; Sherry S Ross; John S Wiener; Jonathan C Routh
Journal:  J Urol       Date:  2014-04-13       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.